ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases--The Japanese version of the EORTC QLQ-BM22].

Bone metastasis is a frequent complication of malignant cancer. Previous clinical trials of bone metastasis have largely focused on skeletal related events (SREs) as objective end-points. However, a subjective health-related outcome such as quality of life (QOL) is also a first-priority principle for all patients with malignant cancer. In response to the need for a comprehensive module to evaluate bone metastasis-specific QOL, the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group has developed a Quality of Life Questionnaire for patients with Bone Metastases (EORTC QLQ-BM22). In this study, we introduce the official Japanese version of the EORTC QLQ-BM22 as a module to evaluate QOL in patients with bone metastasis. This module has been developed to be used together with the EORTC QLQ-C30, a QOL scale for patients with cancer, or with its shortened version, EORTC QLQ-C-15-PAL.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app